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Résumé de la thèse: Impact of total ischemic time on manual thrombus aspiration 
benefit during primary percutaneous coronary intervention, American Heart 
Journal, manuscript accepted May 30, 2018. 
Importance du sujet L’infarctus myocardique aigu est une pathologie fréquente avec chaque année en Suisse 15'000 évènements recensés et constitue la cause directe de 40% de décès chez les personnes âgées de plus de 65 ans. Une reperfusion coronarienne rapide est primordiale surtout s’il s’agit d’une occlusion artérielle thrombotique se manifestant par un sus-décalage du segment ST à l’ECG (en anglais : ST-segment elevation myocardial infarction, ou STEMI). Le ‘gold standard’ étant une revascularisation percutanée, il reste débattu si l’aspiration manuelle du thrombus pendant cette intervention est bénéfique. 
Objectif Effectuer une étude rétrospective de patients inclus dans un large registre national (Acute Myocardial Infarction in Switzerland Plus, ou AMIS Plus) en comparant le traitement par revascularisation percutanée avec versus sans thromboaspiration. 
Méthodes Une analyse multivariée a été conduite chez des patients avec STEMI traités par revascularisation percutanée en comparant le groupe avec thromboaspiration et le groupe sans thromboaspiration. Les résultats ont été ajustés par rapport à l’âge, le sexe, la présence de diabète, hypertension artérielle, insuffisance rénale chronique, choc cardiogénique, infarctus antérieur et d’une maladie coronarienne pluri-tronculaire. Pour des analyses supplémentaires les patients ont été stratifiés selon la durée de leurs symptômes jusqu’à l’intervention, en temps d’ischémie court (<3 heures), moyen (3-6 heures) et long (>6 heures). Le critère principal (endpoint primaire) est la mortalité intra-hospitalière de toute cause et le critère secondaire (endpoint secondaire) les évènements cardio-vasculaires majeurs soit un nouvel infarctus myocardique, un accident cérébro-vasculaire ischémique, ou le décès (en anglais : Major Adverse Cardiovascular Event, ou MACE). 
Résultats Entre 2008 et 2014, 4154 patients avec STEMI ont été inclus et presque la moitié (48%) traitée par thromboaspiration. Après une analyse multivariée la mortalité intra-hospitalière de toutes causes confondues n’est pas significativement différente entre les deux groupes (OR 1.29; 95%CI 0.83-1.98 ; p=0.26) mais le groupe de patients avec thromboaspiration présente plus de MACE (OR 1.52 ; 95%CI 1.05-2.19 ; p=0.03).   
Conclusions Dans un large registre national de patients avec STEMI la thromboaspiration manuelle n’est pas associée à une diminution du risque de décès intra-hospitalier indépendamment du temps d’ischémie, mais au contraire semble aboutir à une augmentation du risque d’évènements cardiovasculaires majeurs. L’augmentation du risque de MACE est notamment significative chez des patients avec une longue durée d’ischémie. 
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Clinical InvestigationsImpact of total ischemic time on manual
thrombus aspiration benefit during primary
percutaneous coronary intervention
Sarah Hugelshofer, MD, a Marco Roffi, MD, b Fabienne Witassek, MS, c Franz R. Eberli, MD, d Thomas Pilgrim, MD, e
Giovanni Pedrazzini, MD, f Hans Rickli, MD, g Dragana Radovanovic, MD, c Paul Erne, MD, h Sophie Degrauwe, MD, b
Olivier Muller, MD PhD, a Pier Giorgio Masci, MD PhD, a Stephan Windecker, MD, e and Juan F. Iglesias, MDb Lausanne
University Hospital, Geneva, University of Zurich, Bern University Hospital, Lugano, Kantonsspital St. Gallen, and
Universita della Svizzera Italiana, SwitzerlandBackground The benefits of manual thrombus aspiration (TA) during primary percutaneous coronary intervention (pPCI)
for ST-elevation myocardial infarction (STEMI) remain uncertain. We assessed the influence of total ischemic time (TIT) on
clinical outcomes among STEMI patients undergoing manual TA during pPCI.
Methods and results We conducted a retrospective study of patients enrolled in the Acute Myocardial Infarction in
Switzerland Plus registry. STEMI patients undergoing pPCI with (TA group) or without (PCI-alone group) manual TA were
stratified based on short (b3 hours), intermediate (3-6 hours), and long (N6 hours) TIT. The primary endpoint was in-hospital all-
cause mortality. The secondary endpoint was in-hospital major adverse cardiac events (MACE), a composite of all-cause death,
myocardial reinfarction and stroke.
Between 2008 and 2014, 4’154 patients (TA 48%) were included. Risk-adjusted in-hospital all-cause mortality was not
different between TA and PCI-alone groups (OR 1.29; 95%CI 0.83-1.98; p=0.26), whereas there was significantly increased
risk of MACE (OR 1.52; 95%CI 1.05-2.19; p=0.03) in patients treated with manual TA compared with PCI-alone. There was
no significant difference between manual TA and PCI-alone with respect to risk-adjusted all-cause mortality according to TIT
groups, but risk-adjusted MACE rates were significantly higher in the group of patients with long TIT treated with manual TA
compared with PCI-alone (OR 2.42; 95%CI 1.16-5.04; p=0.02).
Conclusion In a large registry of STEMI patients, manual TA was not associated with lower risk-adjusted in-hospital all-
cause mortality compared with PCI-alone regardless of TIT but was associated with significantly greater risk of MACE. In
patients with prolonged TIT, manual TA was associated with higher risk-adjusted MACE rates compared with PCI-alone.
(Am Heart J 2018;204:34-42.)Primary percutaneous coronary intervention (pPCI) is
the most effective reperfusion strategy for patients with
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l,5(STEMI).1 Nonetheless, the success of pPCI for STEMI is
currently limited by suboptimal myocardial tissue reper-
fusion despite achieving epicardial coronary patency,
mainly secondary to distal thrombus embolization and
microvascular obstruction. Suboptimal coronary reperfu-
sion in patients with STEMI is associated with worse
outcomes.2,3
Manual thrombus aspiration (TA) during pPCI has been
introduced with the intent to reduce thrombus burden,
prevent distal embolization and increase microvascular
perfusion. However, the clinical benefit of manual TA
during pPCI remains uncertain. A single-center random-
ized trial demonstrated improved myocardial reperfusion
and a nearly 50% reduction in one-year mortality among
STEMI patients undergoing manual TA compared with
pPCI alone,4,5 whereas two recent large-scale multicenter
randomized trials powered for clinical outcomes6-9 and
large-scale meta-analysis10 have consistently shown that
Hugelshofer et al 35
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Volume 204, Number 0routine manual TA during pPCI for STEMI did not reduce
all-cause mortality and major adverse cardiovascular
events (MACE) during short- and long-term follow-up
compared with pPCI alone and might be associated with
an increased risk of stroke. Accordingly, current Europe-
an Society of Cardiology1 and American College of
Cardiology/American Heart Association guidelines11 do
not recommend the routine use of manual TA during
pPCI for STEMI. However, the question of whether
selected patient subgroups may benefit from manual TA
during pPCI remains matter of debate due to the lack of
robust randomized evidence.
Total ischemic time (TIT), defined as time from
symptom onset to reperfusion therapy, is an important
independent predictor of myocardial reperfusion, myo-
cardial infarct size, and long-term clinical outcomes in
patients undergoing pPCI for STEMI.12-15 There is
conflicting evidence with regards to the potential
interaction between TIT and the effect of manual TA
during pPCI. Recent studies have suggested beneficial
effects of manual TA over pPCI alone with respect to
myocardial reperfusion16 and rates of death or MACE17
among patient with longer times to treatment. Contrari-
wise, in a recent large-scale meta-regression analysis, TIT
did not influence any potential benefits observed with
manual TA.10 We aimed to assess the impact of TIT on the
clinical benefits of manual TA in a large cohort of STEMI
patients undergoing pPCI in contemporary practice.Methods
Study design
We conducted a retrospective analysis of patients
included in AMIS (Acute Myocardial Infarction in
Switzerland) Plus, a large, nationwide, multicenter
registry of patients admitted with acute coronary
syndrome (ACS) to hospitals in Switzerland. The design
of the registry has been described previously.18 Briefly,
AMIS Plus prospectively collects 230 items on baseline
characteristics, out-of-hospital and early in-hospital man-
agement, reperfusion strategy, immediate drug therapy,
hospital course, discharge medication and follow-up of
patients presenting with ACS in Switzerland. From 106
hospitals treating ACS in Switzerland, 82 hospitals
temporarily or continuously enrolled patients in AMIS
Plus. Participating centers provide blinded data for each
patient through a web-based database and are strongly
encouraged to enroll all consecutive patients fulfilling
inclusion criteria to avoid selection bias. Hospital data are
provided and completed by the treating physician or a
trained study nurse. All data are checked for complete-
ness, plausibility and consistency by the AMIS Plus Data
Center at the Epidemiology, Biostatistics and Prevention
Institute of the University of Zurich, Switzerland.6Study population
We examined a cohort of STEMI patients included in
AMIS Plus who underwent pPCI within 12 hours of
symptom onset from January 2008 to December 2014.
STEMI was defined by presence of symptoms of ischemia
and at least 1-mm (presumed) new persistent ST-segment
elevation in ≥2 contiguous limb leads or at least 2-mm in
≥2 contiguous precordial leads, or (presumed) new left
bundle branch block. Manual TA was performed at the
operator’s discretion using one of the approved aspira-
tion devices and was followed by conventional PCI to the
culprit lesion. No mechanical aspiration devices were
included in this analysis. The choice of antithrombotic
therapy was left to the discretion of the treating
physician. Epicardial reperfusion was assessed using the
Thrombolysis in Myocardial Infarction (TIMI) flow
grading system before and after pPCI. TIT was defined
as time from symptom onset until pPCI. Patients were
divided into two groups based on the use of manual TA
before PCI (TA group) or PCI only (PCI-alone group). The
TA group included all patients in whom manual TA was
attempted. Patients were further stratified into three time
groups based on TIT, defined as short (b3 hours),
intermediate (between 3 to 6 hours), and long (N6 hours).
Study endpoints
The primary endpoint was all-cause mortality during
the hospital period. The secondary endpoint was MACE, a
composite of all-cause death, non-fatal myocardial rein-
farction, or stroke, during the hospital period. Non-fatal
myocardial reinfarction was defined as presence of
recurrent symptoms with concomitant suggestive elec-
trocardiogram (ECG) changes and/or at least two-fold
increase in cardiac biomarkers above the upper limit of
normal. Stroke was defined as the presence of a new focal
neurological deficit thought to be of vascular origin, with
signs or symptoms lasting more than 24 hours.
Statistical analysis
The results are presented as percentages for categorical
variables and analyzed using the chi-square test or the
Fisher's exact test as appropriate. Continuous normally
distributed variables are expressed as means ± standard
deviation (SD) and compared using the two-tailed
Student's t-test. Continuous non-normally distributed
variables were analyzed using the Mann-Whitney U test
and expressed as median and interquartile ranges (IQR).
A multivariate logistic regression analysis was performed
to account for confounding variables and potential bias
between the two treatment groups, including age,
gender, diabetes, hypertension, chronic renal failure,
multivessel disease, anterior infarction and cardiogenic
shock. The results are expressed as odds ratio (OR) and
95% confidence interval (CI). A p-value of b0.05 was
considered as statistically significant. SPSS software
36 Hugelshofer et al
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Month 2018(version 24.0.0, SPSS Inc., Chicago, Illinois, USA) was
used for all statistical analyses.
Ethical considerations
The study protocol complies with the Declaration of
Helsinki regarding investigations on humans and was
approved the Swiss board for data security and all
regional ethics commissions.
Funding
No extramural funding was used to support this
analysis. The authors are solely responsible for the design
and conduct of this study, all study analyses, the drafting
and editing of the paper and its final contents.Results
From 1st January 2008 to 30th April 2014, 18’177
patients with ACS from 51 Swiss hospitals were
prospectively enrolled in the AMIS Plus registry. Among
9’715 patients presenting with STEMI during the study
period, 8’529 underwent pPCI and the use of manual TA
was documented for 5’538 patients. We further excluded
1’384 patients due to missing data on TIT (n=1’199), peak
CK level (n=89) and glycoprotein (GP) IIb/IIIa inhibitors
use (n=96). A total of 4’154 patients were included for
analysis. Of these, 1’988 (48%) underwent manual TA
during pPCI, whereas 2’166 patients (52%) were treated
with PCI only. The study population was further divided
according to the TIT into three subgroups: short TIT
b3 hours (1’644 patients; TA group, 843 patients; PCI-
alone group, 801 patients), intermediate TIT between
3 to 6 hours (1’364 patients; TA group, 668 patients; PCI-
alone group, 696 patients), and long TIT between
N6 hours (1’146 patients; TA group, 477 patients; PCI-
alone group, 669 patients) (Figure 1).
Baseline characteristics
The baseline characteristics of the study population
are listed in Table I. Overall, patients in the TA
group were younger, more likely male, and had lower
rates of hypertension and diabetes mellitus compared
with patients in the PCI-alone group. Patients
undergoing manual TA had shorter median TIT [200
(IQR 136 to 347) vs. 224 minutes (IQR 146 to 442);
pb0.001] compared with patients undergoing PCI only.
The rates of cardiogenic shock and anterior MI were not
statistically different between the two groups. Patients in
the TA group were less often on aspirin or a P2Y12
receptor antagonist prior to admission compared with
patients in the PCI-alone group. There were higher rates
of GP IIb/IIIa inhibitors use in the TA group than in the
PCI-alone group (40.1% vs. 18.9%; pb0.001). Patients
undergoing manual TA were less likely to have multi-
vessel coronary artery disease (17.1 vs. 26.9%; pb0.001)7and the culprit artery was more frequently located on the
left anterior descending artery and right coronary artery
compared with patients undergoing pPCI only. Notably,
patients in the manual TA group were more likely to have
TIMI flow 0 before pPCI (79.8% vs. 56.4%; pb0.001)
compared with PCI-alone patients. Procedural success
rates, defined as rates of post-procedural TIMI flow grade
3, was not statistically different between manual TA and
PCI-alone treated patients (p=0.57). The baseline and
procedural characteristics of the study population
according to TIT group are summarized in Supplemen-
tary Table 1.
Univariate analysis
Crude rates of in-hospital all-cause mortality [3.8% vs.
3.6%; odds ratio (OR) 1.06; 95% CI 0.77 to 1.47; p=0.71],
MACE (5.1% vs. 4.2%; OR 1.22; 95% CI 0.91 to 1.63; p=
0.18), stroke (0.6% vs. 0.3%; OR 1.72; 95% CI 0.66 to 4.43;
p=0.27) and cardiogenic shock (2.7% vs. 2.8%; OR 0.93;
95% CI 0.64 to 1.37; p=0.72) were not statistically
different between TA and PCI-alone groups in the overall
patient population (Table II). There was a significantly
increased unadjusted risk of myocardial reinfarction
(1.0% vs. 0.4%; OR 2.60; 95% CI 1.14 to 5.96; p=0.02)
in patients undergoing manual TA compared with
patients in the PCI-alone group (Table II).
In patients with short (b3 hours) and intermediate (3-6
hours) TIT, there were no significant differences
between manual TA and PCI alone with respect to
crude rates of in-hospital all-cause mortality (4.3% vs.
5.0%; p=0.56, and 2.5% vs. 3.0%; p=0.63, respectively)
and MACE (5.6% vs. 5.5%; p=0.94, and 4.0 % vs. 4.2%; p=
0.91) (Table III). There was no significant continuous
association between TIT and in-hospital all-cause mortal-
ity (p=0.20) and MACE (p=0.30). In patients with
prolonged TIT (N6 hours), crude rates of all-cause death
(4.6% vs. 2.4%; OR 1.97, p=0.04) and MACE (5.7% vs.
2.4%; OR 2.17, p=0.01) were significantly higher with
manual TA compared with PCI alone. However, interac-
tion testing between manual TA versus PCI only and TIT
groups did not demonstrate significant interaction with
respect to all-cause mortality (joint p-value 0.09) and
MACE (joint p-value for MACE p= 0.09).
Among patients in the TA group, there were no
significant differences with respect to crude rates of all-
causemortality (4.3%, 2.5%, and 4.6% for TITb3, 3 to 6, and
N6 hours, respectively, p for trend=0.12) and MACE (5.6%,
4%, 5.7% for TITb3, 3 to 6, and N6 hours, respectively, p for
trend=0.32) according to TIT (Table III). Unadjusted in-
hospital all-cause mortality rates were marginally lower in
patients with intermediate TIT (3-6 hours) undergoing
manual TA compared with patients with either shorter
(2.5% vs. 4.3%, p=0.09) or longer (2.5% vs. 4.6%, p=0.07)
times to treatment (Table III). However, there was no
significant association between in-hospital all-cause mor-
tality or MACE and continuous TIT in both TA (p=0.99 and
Figure 1
STUDY FLOW CHART ACS: acute coronary syndrome; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary
intervention; STEMI: ST-segment elevation myocardial infarction; UA: unstable angina.
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Volume 204, Number 0p=0.82, respectively) and PCI-alone (p=0.11 and p=0.32,
respectively).
Multivariate analysis
Multivariable analysis was performed to account for
confounding variables and potential bias between treat-
ment groups. After adjustment for age, gender, diabetes
mellitus, hypertension, TIT, chronic renal failure, cardio-
genic shock, anterior STEMI, and multivessel disease, in-
hospital all-cause mortality rates were not significantly
different between manual TA and PCI-alone groups (OR
1.29; 95% CI 0.83-1.98; p=0.26) (Table II, Figure 2),
whereas there was a significantly increased adjusted risk
of MACE (OR 1.52; 95% CI 1.05-2.19; p=0.03) among
patients treated with manual TA compared with PCI
alone (Table IV), driven by an increased risk of
myocardial reinfarction (OR 2.45; 95% CI 1.05-5.76; p=
0.04) (Table II). There was no significant difference
between manual TA and PCI alone with respect to risk-8adjusted all-cause mortality according to TIT (Table IV).
Compared with PCI-only treated patients, there was a
significantly increased adjusted risk of MACE (OR 2.42;
95% CI 1.16-5.04; p=0.02) among patients with pro-
longed TIT (N6 hours) undergoing manual TA (Table IV).
However, no significant interaction between manual TA
and TIT groups was found for in-hospital all-cause
mortality (p=0.68) and MACE (p=0.57). Increasing age
(per additional year, OR 1.05; 95% CI 1.03-1.07; pb0.001)
and cardiogenic shock (OR 25.6; 95% CI 16.26-40.28;
pb0.001), but neither manual TA (OR 1.29; 95% CI 0.83-
1.98; p=0.26) nor TIT (TIT 3-6 hours, OR 0.73; 95% CI
0.43-1.25; p=0.25, and TIT N6 hours, OR 1.06; 95% CI
0.63-1.18; p=0.82, compared with TIT b3 hours, respec-
tively), were independent predictors of in-hospital all-
cause mortality (Figure 2). Similarly, increasing age (per
additional year, OR 1.03; 95% CI 1.01-1.04; p=0.001),
anterior myocardial infarction (OR 1.46; 95% CI 1.01-
2.10; p=0.04), cardiogenic shock (OR 17.41; 95% CI
Table I. Baseline and procedural characteristics
Characteristic Thrombus aspiration group (n=1’988) PCI-alone group (n=2’166) p value
Age (years) 61 ± 12.4 63.9 ± 12.7 b0.001
Male gender 1582 (79.6) 1614 (74.5) b0.001
Body mass index (kg/m2) 27 ± 4.3 27 ± 4.5 0.98
Hypertension 977/1905 (51.3) 1170/2042 (57.3) b0.001
Dyslipidemia 1019/1818 (56.1) 1052/1916 (54.9) 0.48
Diabetes mellitus 266/1946 (13.7) 338/2062 (16.4) 0.002
Smoking status 0.29
Never 551/1848 (29.8) 615/1915 (32.1)
Former 433/1848 (23.4) 443/1915 (23.1)
Current 864/1848 (46.8) 857/1915 (44.8)
Total ischemic time, min (median/IQR) 200 (136;347) 224 (146;442) b0.001
Previous myocardial infarction 202/1950 (10.4) 263/2098 (12.5) 0.03
Heart failure 18/1765 (1.0) 37/2066 (1.8) 0.06
Renal disease 60/1946 (3.1) 86/2088 (4.1) 0.09
Cerebrovascular disease 71/1946 (3.6) 83/2088 (4.0) 0.62
Previous PCI 235/1950 (12.1) 255/2098 (12.2) 0.92
Previous CABG 36/1950 (1.8) 64/2098 (3.1) 0.01
Killip class 4 111/1974 (5.6) 112/2159 (5.2) 0.76
Killip class N2 143/1974 (7.2) 152/2159 (7.0) 0.81
Anterior myocardial infarction 814/1984 (41) 939/2162 (43.4) 0.12
Medical treatment prior to admission
Aspirin 395/1794 (22.0) 515/1930 (26.7) 0.001
P2Y12 antagonist 113/1988 (5.7) 172/2166 (7.9) 0.004
Oral anticoagulation 55/1786 (3.1) 67/906 (3.5) 0.46
Medical treatment during admission
Aspirin 1944/1983 (98.0) 2130/2166 (98.3) 0.46
P2Y12 antagonist 1909/1988 (96.0) 2112/2166 (97.5) 0.007
Glycoprotein IIb/IIIa antagonist 797/1988 (40.1) 409/2166 (18.9) b0.001
Anticoagulation 1848/1988 (93) 1943/2166 (89.7) b0.001
Thrombolysis 7/1988 (0.4) 6/2166 (0.3) 0.67
Number of diseased vessels
1 1000/1988 (50.3) 902/2166 (41.6) b0.001
2 569/1988 (28.6) 666/2166 (30.7) 0.13
3 339/1988 (17.1) 582/2166 (26.9) b0.001
Infarct-related artery 0.005
Left main coronary artery 9/1358 (0.7) 20/1228 (1.6)
Left anterior descending artery 575/1358 (42.3) 538/1228 (43.8)
Right coronary artery 588/1358 (43.3) 464/1228 (37.8)
Left circumflex artery 171/1358 (12.6) 187/1228 (15.2)
TIMI flow grade before PCI b0.001
0 1125/1410 (79.8) 795/1410 (56.4)
1 93/1410 (6.6) 193/1410 (13.7)
2 90/1410 (6.4) 184/1410 (13)
3 102/1410 (7.2) 238/1410 (16.9)
TIMI flow grade after PCI 0.008
0 8/1749 (0.5) 24/1719 (1.4)
1 19/1749 (1.1) 12/1719 (0.7)
2 85/1749 (4.9) 66/1719 (3.8)
3 1637/1749 (93.6) 1617/1719 (94.1)
Data are mean (±SD) or number of patients (%). IQR: interquartile range.
CABG, Coronary artery bypass graft; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.
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Month 201811.65-26.01; pb0.001) and manual TA (OR 1.52; 95% CI
1.05-2.20; p=0.03), but not TIT (TIT 3-6 hours, OR 1.00;
95% CI 0.65-1.55; p=0.99, and TIT N6 hours, OR 1.02; 95%
CI 0.65-1.61; p=0.93, compared with TIT b3 hours,
respectively), were independent predictors of in-hospital
MACE.
When adding TIMI flow grade 0 before pPCI to the
multivariate model (n=2’359 patients), there was no9significant difference between manual TA and PCI alone
with respect to risk-adjusted all-cause mortality (OR 1.40;
95% CI 0.76-2.40; p=0.30) (Supplementary Table 2).
Increasing age (per additional year, OR 1.04; 95% CI 1.01-
1.07; p=0.002), diabetes mellitus (OR 2.27; 95% CI 1.22-
4.21; p=0.01), anterior myocardial infarction (OR 1.99;
95% CI 1.14-3.49; p=0.02) and cardiogenic shock (OR
24.42; 95% CI 13.51-44.16; pb0.001), but neither TIMI
Table II. In-hospital clinical outcomes
UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS
OUTCOMES Thrombus aspiration group PCI-alone group Unadjusted OR 95% CI p value Adjusted
OR
95% CI p value
All-cause mortality 75/1988 (3.8) 77/2166 (3.6) 1.06 0.77-1.47 0.71 1.29 0.83-1.98 0.26
MACE 101/1988 (5.1) 91/2166 (4.2) 1.22 0.91-1.63 0.18 1.52 1.05-2.19 0.03
Myocardial reinfarction 19/1987 (1.0) 8/2166 (0.4) 2.60 1.14-5.96 0.02 2.45 1.05-5.76 0.04
Stroke 11/1987 (0.6) 7/2166 (0.3) 1.72 0.66-4.44 0.27 2.14 0.76-6.01 0.15
Cardiogenic shock 48/1806 (2.7) 61/2144 (2.8) 0.93 0.64-1.37 0.72 1.11 0.72-1.72 0.64
Data are number of patients (%). CI: confidence interval, OR: odds ratio.
MACE, Major adverse cardiovascular events, composite of all-cause mortality, myocardial reinfarction, or stroke; PCI, percutaneous coronary intervention.
Table III. In-hospital clinical outcomes according to total ischemic time
Total
ischemic
time
ALL-CAUSE MORTALITY MACE
Overall TA group
PCI-alone
group
Unadjusted
OR 95% CI
p
value Overall TA group
PCI-alone
group
Unadjusted
OR 95% CI
p
value
b3 hours 76/1644
(4.6)
36/843
(4.3)
40/801
(5.0)
0.85 0.54-
1.35
0.56 91/1644
(5.5)
47/843
(5.6)
44/801
(5.5)
1.02 0.67-
1.55
0.94
3 – 6
hours
38/1364
(2.8)
17/668
(2.5)
21/696
(3.0)
0.84 0.44-
1.61
0.63 56/1364
(4.1)
27/668
(4.0)
29/696
(4.2)
0.97 0.57-
1.65
0.91
N6 hours 38/1146
(3.3)
22/477
(4.6)
16/669
(2.4)
1.97 1.03-
3.79
0.04 45/1146
(3.9)
27/477
(5.7)
18/669
(2.7)
2.17 1.18-
3.98
0.01
Data are number of patients (%). CI: confidence interval, OR: odds ratio.
MACE, Major adverse cardiovascular events; PCI, percutaneous coronary intervention; TA, thrombus aspiration.
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Volume 204, Number 0flow grade 0 before pPCI (OR 0.59; 95% CI 0.29-1.20;
p=0.15) nor TIT (TIT 3-6 hours, OR 0.66; 95% CI 0.33-
1.31; p=0.23, and TIT N6 hours, OR 1.05; 95% CI 0.54-
2.06; p=0.88, compared with TIT b3 hours, respective-
ly), were independent predictors of in-hospital all-cause
mortality (Supplementary Table 2).Discussion
The major findings of the present study can be
summarized as follows: (1) manual TA during pPCI did
not reduce risk-adjusted in-hospital all-cause mortality
rates compared with PCI alone irrespective of TIT; (2)
manual TA during pPCI was associated with a significant-
ly increased adjusted risk of MACE compared with PCI
alone; and (3) manual TA in patients with prolonged TIT
was associated with significantly increased risk-adjusted
in-hospital MACE rates compared with PCI alone. To the
best of our knowledge, this is the largest study evaluating
the influence of TIT on the clinical benefit of manual TA
during pPCI.
In our large registry of STEMI patients undergoing pPCI,
routine manual TA did not reduce the risk of in-hospital
all-cause death, MACE, and cardiogenic shock when
compared with PCI alone, whereas there was a trend10towards an increased risk of stroke. These findings are
consistent with the results of two recent large-scale
randomized clinical trials6-9 and subsequent meta-
analyses10,20 demonstrating that routine manual TA
during PCI for STEMI does not improve clinical outcomes
at the expense of an increased risk of stroke, whereas there
was a trend towards reduced cardiovascular death in the
subgroup of patients with high thrombus burden.10
However, current evidence is mainly limited to patients
presenting within the first hours after symptom onset6-9
and the impact of TIT on manual TA efficacy in the
contemporary pPCI era is currently uncertain, owing to the
contradictory results of previous studies.10,14, 16,17,19,23-27
Prolonged TIT in the setting of STEMI has been
associated with suboptimal myocardial reperfusion, larger
infarct size and increased 1-year mortality rates.12-15,21
Patients presenting late after symptom onset display
particularly high thrombus burden owing to long ischemic
times, but data on manual TA efficacy in the subgroup of
patients with STEMI presenting late after symptom onset
are scarce and matter of debate. Prior small-sized random-
ized studies16,24 and post-hoc meta-regression analysis of
early randomized trials17 suggested that manual TA may
indeed bemore effective in the subgroup of late-presenting
patients undergoing pPCI. In the VAcuuM asPIration
thrombus REmoval (VAMPIRE) study, manual TA was
Figure 2
RISK-ADJUSTED IN-HOSPITAL ALL-CAUSE MORTALITY. Predictors of in-hospital all-cause mortality after adjustment for age, gender,
cardiovascular risk factors, TIT, multivessel disease, and chronic renal failure.CI: confidence interval; OR: odds ratio; TIT: total ischemic time.
Table IV. Risk-adjusted in-hospital clinical outcomes in patients undergoing manual thrombus aspiration according to total ischemic time
Total
ischemic
time
ALL-CAUSE MORTALITY MACE
Risk-adjusted OR 95% CI p value Risk-adjusted OR 95% CI p value
Overall 1.29 0.83-1.98 0.26 1.52 1.05-2.19 0.03
b 3 hours 1.25 0.64-2.45 0.51 1.59 0.88–2.88 0.13
3-6 hours 0.88 0.38-2.04 0.77 1.08 0.58-2.04 0.81
N6 hours 1.93 0.85-4.37 0.12 2.42 1.16-5.04 0.02
CI, Confidence interval; MACE, major adverse cardiovascular events; OR, odds ratio.
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Month 2018shown to significantly improvemyocardial reperfusion and
reduce adverse ischemic events compared with PCI-alone
when performed among patients presenting between 6
and 24 hours after symptom onset compared to patients
treated with early (b6 hours) reperfusion.24 However, in
the largest cohort of late-presenting STEMI patients
undergoing cardiac magnetic resonance imaging for the
assessment of myocardial reperfusion, manual TA did not
reduce the extent of microvascular obstruction and clinical
outcomes compared with PCI alone as the result of only a
moderate amount of salvageable myocardium at later
stages.26 Our results demonstrate no significant association
with respect to risk-adjusted all-cause mortality between
manual TA and PCI alone, whereas manual TA was
associated with a significantly increased adjusted risk of
MACE compared with pPCI alone, mainly driven by an11increased risk of myocardial reinfarction. These findings
suggest that manual TAmay not be appropriate for patients
with prolonged TIT and add new insights on the crucial
issue of the appropriate selection of STEMI patient subsets
that might derive benefit from the selective use of manual
TA during pPCI.
The results of the present analysis are consistent with
several previous large studies.4-10,19,23 No influence of
TIT on manual TA efficacy was observed in the single-
center Thrombus Aspiration During Percutaneous
Coronary Intervention in Acute Myocardial Infarction
Study (TAPAS)4,5 and the large multicenter Thrombus
Aspiration in ST-Elevation Myocardial Infarction in
Scandinavia (TASTE)6,7 and Trial of Routine Aspiration
Thrombectomy With PCI Versus PCI Alone (TOTAL)8,9
randomized trials. Individual patient-level meta-analysis of
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Volume 204, Number 0these trials did not demonstrate significant differences
with respect to cardiovascular death at 30 days between
manual TA and PCI-only in patients with TIT N6 hours and
between 6 and 12 hours, whereas numerically higher
cardiovascular mortality rates were found among patients
with prolonged (N12 hours) times from symptom onset in
the manual TA group compared with PCI-alone treated
patients.19 Furthermore, meta-regression analysis of a
large meta-analysis did not identify any potential benefits
of manual TA with respect to all-cause death based on
TIT.10 However, at variance from the results of our large
contemporary STEMI cohort, the study did not demon-
strate significant differences with respect to MACE based
on TIT.10
The mechanistic insights underlying the influence of
TIT on clinical outcomes following manual TA cannot be
directly derived from our study. However, intracoronary
thrombus formation in STEMI patients is a dynamic
process and thrombus composition may play an impor-
tant role. Whereas thrombotic material is relatively soft at
initial stages (low fibrin content, high platelet content),
thrombus becomes more organized over time (high fibrin
content, low platelet content). Thus, thrombus is possibly
less suited for manual TA and more likely to disrupt
resulting in significant iatrogenic distal embolization at
later stages,21 where additionally there is no, or only
minimal, residual myocardium to be salvaged.26 Finally,
as observed in the current analysis, patients undergoing
manual TA are substantially younger, with one-vessel
disease and without prior myocardial infarction com-
pared with patients treated with PCI-alone. This lower
atherosclerotic burden might result in reduced tolerance
to acute myocardial ischemia and increased susceptibility
to worse clinical outcomes among patients undergoing
manual TA.
Our data must be interpreted in view of several
limitations. First, our study includes all limitations of a
large nationwide registry, such as potential bias and
unmeasured confounders associated with nonrando-
mized studies. Highest-risk patients may not have been
considered for an invasive management and we cannot
exclude the possibility of underreporting of clinical
outcomes. In addition, the potential effect of confounding
by indication on MACE rates cannot be formally
excluded. The use of manual TA was left at the discretion
of the operator and a potential selection bias with
inclusion of lesions with higher thrombus burden in the
TA group cannot be excluded. Despite the large size of
our study population, our cohort may not have the power
to detect differences in rates of in-hospital all-cause
mortality related to the use of manual TA among
subgroups of STEMI patients. All-cause mortality rates
reported in our large contemporary cohort of STEMI
patients treated with pPCI were low, suggesting a
potential quantitative interaction, thus underestimating
the treatment benefit in this ‘low-risk’ patient population.12Finally, thrombus grade and findings on the results of
manual TA such as no retrieval of debris or failure of the
catheter to cross the culprit lesion were not recorded.Conclusion
In a large cohort of patients with STEMI undergoing
pPCI, manual TA was not associated with lower risk-
adjusted in-hospital all-cause mortality compared with
PCI-alone regardless of TIT but was associated with
significantly greater risk of MACE. In patients with
prolonged TIT, manual TA was associated with higher
risk-adjusted MACE rates compared with PCI-alone.
These results warrant confirmation by further analyses
from existing randomized clinical trials.
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ahj.2018.05.019.References
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